The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
18F-16β-fluoro-5α-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Karen A. Autio
No relevant relationships to disclose
Josef J. Fox
No relevant relationships to disclose
Xiaoyu Jia
No relevant relationships to disclose
Glenn Heller
No relevant relationships to disclose
Heiko Schöder
No relevant relationships to disclose
John Humm
No relevant relationships to disclose
Eric C. Haupt
No relevant relationships to disclose
Coursen Schneider
No relevant relationships to disclose
Howard I. Scher
No relevant relationships to disclose
Steven M. Larson
No relevant relationships to disclose
Michael J. Morris
No relevant relationships to disclose